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A BST R AC T   
 
Aim: Polycystic ovary syndrome (PCOS) is a multifactorial, endocrine, and metabolic disorder seen 
in 10%-20% of women of reproductive age. Due to the close relationship observed between the 
increased risk of type 2 diabetes and insulin resistance and the polymorphism of the fatty acid binding 
protein 1 (FABP1) gene rs2197076 single nucleotide polymorphism (SNP), we investigated the 
frequency of the FABP1 gene rs2197076 SNP in patients with PCOS. 
Methods: This is a prospective case-control study. The study included 151 women—75 patients with 
PCOS and 76 healthy women. A real-time polymerase chain reaction was performed for the FABP1 
rs2197076 polymorphism. Additionally, biochemical and hormonal levels of the patients were 
studied.  
Results: Menstrual irregularities, the body mass index (BMI), hirsutism scores, the luteinizing 
hormone / follicular stimulating hormone ratio, dehydroepiandrosterone sulfate and testosterone 
levels were significantly higher in the PCOS group than in the control. There was no significant 
difference between the PCOS and control groups in terms of FABP1 rs2197076 genotype distribution 
and FABP1 rs2197076 allele frequency distribution. 
Conclusion: There was no increase in the genotype distribution and allelic frequency of the FABP1 gene 
rs2197076 SNP in PCOS patients. Further studies are needed on this subject. 
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Introduction 
Polycystic ovary syndrome (PCOS) is a 
multifactorial, endocrine, and metabolic 
disorder seen in 10%–20% of women of 
reproductive age [1]. It is characterized by 
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obesity, hirsutism / hyperandrogenism, oligo-
anovulation, and polycystic ovaries identified 
by ultrasound [2].  
PCOS is associated with type 2 diabetes 
mellitus, dyslipidemia, metabolic syndrome, 
and an increased risk of cardiovascular disease 
[3]. Insulin resistance, hypothalamic-pituitary-
ovarian axial dysfunction, ovarian 
steroidogenesis dysregulation, and genetic 
factors are thought to play a role in the 
etiopathogenesis of PCOS [4,5,6]. Studies 
have shown that single nucleotide 
polymorphisms (SNPs) of various genes are 
closely related to PCOS [7]. 
Fatty acid binding proteins (FABPs) are a 
family of lipid-binding proteins that play a role 
in lipid metabolism and signal transduction [8]. 
They act as molecular chaperones and are 
regarded as critical agents of metabolic and 
inflammatory processes both locally and 
systemically [9]. Liver fatty acid binding 
protein (L-FABP, also known as FABP1) is a 
protein found in the cytoplasm of hepatocytes 
that may also be present in intestinal cells and 
to a lesser extent in the core and outer 
mitochondrial membrane. Unlike the other 
members of the FABP family, FABP1 contains 
two long-chain fatty acid (LCFA) molecules. 
FABP1 mediates transcriptional programs by 
delivering lipids to nuclear receptors [10,11]. 
FABP1 plays an important role as a 
cryoprotectant by controlling the presence of 
LCFAs and oxidative metabolites [12]. FABP1 
SNP rs2197076 polymorphism is reported 
closely related to type 2 diabetes and insulin 
resistance [13]. Due to the close relationship 
observed between the increased risk of type 2 
diabetes and insulin resistance and the 
polymorphism of the FABP1 gene rs 219076, 
we investigated whether there is a link between 
PCOS etiopathogenesis and the FABP1 SNP 
rs2197076 polymorphism. 
Methods  
This prospective case-control study was 
carried out with the approval of the ethics 
committee of the Faculty of Medicine of Bolu 
Abant Izzet Baysal University (06 /04 /2016, 
document number 63). The study included 151 
women, 75 patients with PCOS and 76 healthy 
women who were admitted to the Gynecology 
and Obstetrics Department. The diagnosis of 
PCOS was based on the Rotterdam criteria [2]: 
1- clinical and/or biochemical 
hyperandrogenism (hirsutism or elevated 
serum total/free testosterone levels); 2- 
oligo/amenorrhea and anovulation; and 3-
polycystic ovarian morphology upon 
ultrasound examination (presence of at least 12 
antral follicles up to 12 mm in diameter and/or 
ovarian volume ≥10 cm3 and increased stromal 
echogenicity). PCOS was diagnosed if two of 
these three criteria were met. Those who read 
and signed the volunteer form were included in 
the study. Patients with thyroid disease, 
hyperprolactinemia, history of malignancy, 
Cushing’s syndrome, or congenital adrenal 
hyperplasia or who were taking hormonal 
drugs, oral antidiabetics, antidepressants, oral 
contraceptives, glucocorticoids, or 
antiandrogenic / antihypertensive drugs were 
excluded from the study. 
Insulin resistance (IR) was defined as 
homeostasis model assessment of insülin 
resistance (HOMA-IR) formula greater or 
equal to 2.6: HOMA-IR = fasting insulin 
(µU/mL) × fasting blood glucose (mg/dL) / 
405. 
Venous blood samples were collected from the 
participants when at rest following one night of 
fasting for biochemical tests. Fasting venous 
blood samples were taken on the second or 
third day of menstruation to perform hormonal 
tests. Blood samples were collected in two 
separate fractions using BD Vacutainer® 
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EDTA tubes and BD Vacutainer® serum 
tubes. BD Vacutainer® serum tubes were 
centrifuged at 8000 rpm for 20 minutes at 4 ° 
C. Luteinizing hormone (LH), follicular 
stimulating hormone (FSH), prolactin (PRL),  
serum insulin,  thyroid stimulating hormone 
(TSH) and total testosterone (T) were 
measured by Abbott Architect i2000SR 
system(Abbott Laboratories, IL, USA) using 
Chemiluminescent assay. Glucose,  
Cholesterol (TC), triglyceride (TG), high-
density lipoprotein (HDL), low-density 
lipoprotein (LDL), and very low-density 
lipoprotein (VLDL) levels in fasting blood 
samples were measured by the Architect c8000 
analyzer system (Abbott Laboratories, IL, 
USA) using kinetic, colorimetric and 
enzymatic methods. In addition, 3 ml blood 
samples were collected in EDTA tubes for 
DNA isolation. 
The DNA was isolated with Roche High Pure 
 
Figure 1. AG Genotype (Heterozygous mutant). 
 
 
 
 
 
 
 
 
 
Figure 3. AA Genotype (Homozygous wild). 
 
 
 
 
 
 
 
 
 
PCR Template Preparation Kit (DNA 
extraction kit). FABP1 gene 
rs2197076 polymorphism was genotyped 
using real-time polymerase chain reaction 
(RT-PCR) with Light Cycler 480-II RT PCR. 
At the end of the RT-PCR study, homozygous 
(wt: wild type), homozygous mutant, and 
heterozygous genotypes were differentiated 
according to the melting point of the peaks 
formed in the melt curve analysis. 
Heterozygous genotypes have two peaks at 
two different melting points (Figure 1), while 
homozygous mutants and homozygous wild 
genotypes have single peaks at the same 
melting point (Figure 2 and 3). In the FABP1 
rs2197076 A/G polymorphism, the Tm 
(melting point) of the A allele was 57.39 ° C, 
and the Tm of the G allele was 51.39 ° C. AA 
genotype is homozygous wild, GG genotype is 
homozygous mutant, AG genotype is 
heterozygous mutant genotypes. 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis 
SPSS 17.0 was used for the statistical analysis. 
Categorical measurements were taken as 
number and percentage. Continuous 
measurements were evaluated as means and 
standard deviations. Chi square tests or Fisher 
test statistics were used to compare categorical 
variables. In comparing continuous 
measurements between groups, a Student’s t 
test was used when parametric test 
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assumptions were provided, and a Mann–
Whitney U test was used when parametric test 
assumptions were not provided. The data 
obtained from the genotype analysis were 
calculated using the Epi Info 3.5.3 statistical 
program. P <0.05 was considered statistically 
significant. 
 
Results 
The study group consisted of 75 women with 
PCOS, and the control group consisted of 76 
healthy women. In the PCOS group, the mean 
age was 23.0 ± 4.9 years, the mean body 
weight was 65.9 kg ± 13.8 kg, the mean body 
mass index (BMI) was 24.9kg/m2 ± 5.8 kg/m2, 
the mean stature was 161.9 ± 5.6 Centimeters. 
The mean waist circumference (WC) was 81.3 
cm ± 12.9 cm, the mean hip circumference 
(HC) was 102.6 cm ± 11.1 cm, and the mean 
WC/HC ratio was 0.79 ± 0.09. In the control 
group, the mean age was 25.3 ± 5 years, the 
mean body weight was 57.3 kg ± 7.3 kg, the 
mean BMI was 21.1 kg/m2 ± 2 kg/m2, the mean 
stature was 162.8 ± 6.5 cm, the mean WC was 
72.3 cm ± 8 cm, the mean HC was 97.8 cm ± 
6.8 cm, and the mean WC/HC ratio was 0.75 
±0.06. Body weight, BMI, WC, HC, and 
WC/HC were found to be significantly higher 
in the PCOS group compared to the control 
group (p<0.01, p<0.01, p<0.01, p<0.01, and 
p<0.01 respectively). No significant difference 
was found between patients’ stature (p=0.316). 
The mean age was significantly higher in the 
control group compared to the PCOS group 
(p<0.01) 
In the PCOS group, there were 70 patients with 
oligo-amenorrhea (93.3%), 50 patients with 
hirsutism (66.6%), 75 patients with polycystic 
ovaries (100%), and 15 patients with a history 
of smoking (20%). In the control group, there 
were 2 women with oligo-amenorrhea (2.6%), 
74 women with regular menstruation (97.4%), 
6 women with hirsutism (7.9%), 18 women 
with polycystic ovaries (23.6%), and 15 
women with a history of smoking (19.7%). 
There were significantly more instances of 
oligo-amenorrhea, hirsutism, and polycystic 
ovaries in the PCOS group (p <0.001, p<0.001, 
and p<0.001, respectively). No significant 
difference was found between the two groups 
in terms of smoking (p=0.608). There were 
significantly more instances of regular 
menstrual cycles in the control group 
(p<0.001).  
 
Table 1. Biochemical and hormonal findings of the 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are expressed as mean ± SD. P<0.05 was considered 
significant. PCOS: Polycystic ovary syndrome, BMI: Body 
mass index, FBG: Fasting blood glocose, HOMA-IR: 
Homeostasis model assessment of insulin resistance, HDL: 
High-density lipoprotein, LDL: Low-density 
lipoprotein, VLDL: Very low-density lipoprotein, 
FSH: Follicle-stimulating hormone, LH: Luteinizing 
hormone, T: testosterone, DHEA: dehydroepiandrostenedion 
sulfate, TSH: Thyroid stimulating hormone. 
 
The biochemical and hormonal findings are 
shown in Table 1. Fasting blood glucose levels 
and insulin levels were significantly higher in 
the PCOS group than in the control group. In 
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both groups, HOMA-IR was calculated for 
insulin resistance and none of them had 2.6 or 
higher HOMA-IR results. The mean HOMA-
IR calculation was 0.87 ± 0.15 in the PCOS 
group and 0.44 ± 0.12 in the control group and 
no significant difference was found between 
the groups. Triglycerides and VLDL levels 
were found to be significantly higher in PCOS 
patients. In the PCOS patient group, FSH was 
found to be significantly lower, and the 
LH/FSH ratio, dehydroepiandrosterone 
sulfate, and testosterone values were 
significantly higher.  
 
Table 2. FABP1 rs2197076 polymorphism 
genotype and allele distribution of working groups. 
 
 
 
 
 
 
 
The data are given as number and percentage. P<0.05 
was considered significant. PCOS: polycystic ovary 
syndrome, FABP1: Fatty acid binding protein 1. 
 
The genotype and allele distribution of the 
rs2197076 polymorphism region of the FABP 
gene for the PCOS and control groups is shown 
in Table 2. In the PCOS group, FABP1 
genotypes were found to be wild type 
homozygous in 4 cases, mutant type 
homozygous in 39 cases, and heterozygous 
genotype in 32 cases. FABP1 genotypes of the 
control group were found to be wild type 
homozygous in 5 cases, mutant type 
homozygous in 38 cases, and heterozygous 
genotype in 33 cases (Figure 4).There was no 
significant difference between the PCOS and 
control groups in terms of homozygous wild 
(AA) and homozygous mutant (GG) FABP1 
genotype distribution (p=0.362).The FABP1 
rs2197076 allele frequency distribution is 
shown in Figure 5. There was no statistically 
significant difference in the frequency of 
alleles between the PCOS and control groups 
(p=0.376). 
 
Figure 4. Genotype distribution for the FABP1 
rs2197076 polymorphism. 
 
 
Figure 5. Allele distribution in PCOS and the 
control groups for the FABP1 rs2197076 
polymorphism. 
 
Discussion 
PCOS is a heterogeneous and multifactorial 
disease. Women with PCOS have an increased 
risk of metabolic diseases, type 2 diabetes, 
insulin resistance, endometrial carcinoma, and 
cardiovascular disease. The FABP1 gene 
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rs2197076 SNP is associated with an increased 
risk of cardiovascular disease, insulin 
resistance, and metabolic syndrome. 
Approximately 65% of the risk of having 
PCOS is thought to be genetic [14]. There has 
been a tendency for candidate gene association 
studies in PCOS genetics studies. Candidate 
gene studies on PCOS have been performed in 
China and Korea [15, 16]. In these studies, 12 
genetic risk loci have been determined for 
PCOS, and these loci have increased in number 
in other ethnic groups [17,18]. Candidate gene 
studies seem to be a powerful method for 
screening sensitive genes associated with 
complex diseases. However, these studies 
mainly focus on individual SNPs and neglect 
the interaction of genes. Some defined SNPs 
seem to lack a relationship that can be 
explained by genetic inheritance. 
Regarding the FABP1 gene, Xue et al. 
investigated the relationship between SNP 
rs2197076 and rs2241883 and PCOS. In their 
study of 221 PCOS women and 198 normal 
women, the authors found a close association 
with rs 2197076 and rs 2241883 
polymorphisms in women with PCOS but no 
association with BMI [19]. In a study of 95 
PCOS women and 45 healthy women, Rashid 
et al. found that the allele and genotype 
frequency of IL-1β, IL-1Ra, and FABP1 gene 
polymorphisms did not differ between the 
PCOS and control groups. However, the IL-1β 
C [-511] T variant, IL-1Ra A allele II intron 2, 
and the A/G variant of the FABP1 (rs2197076) 
A allele showed a significant correlation with 
many metabolic features associated with 
PCOS [20]. In our study, we found no 
difference in the distribution of FABP1 gene 
rs2197076 SNP alleles among PCOS women 
and healthy women. Although the average 
BMI of the patient group was higher than that 
of the control group, no significant difference 
was found between the groups in terms of 
FABP1 gene distribution. 
Cui et al. investigated the incidence of SNP 
allele in 15 women with polycystic ovary 
syndrome, 746 women with oligo-anovulation, 
278 women with hyperandrogenism, and 536 
women with polycystic ovaries identified by 
ultrasound [21]. In this study, rs13405728, 
rs2059807, and rs4385527 allele frequency 
were found to be significant in oligo-
anovulatory women, rs4385527 allele 
frequency was found to be significant in 
women with hyperandrogenism, rs13429458, 
rs12478601, rs10818854 and rs4385527 allele 
frequency in women with polycystic ovaries 
were found to be significant, independent of 
BMI and age. In addition, the frequency of the 
SNP rs4385527 allele was found to be related 
to all three criteria. Lee et al. [16] studied 862 
women with PCOS and 860 healthy women. 
Seven of the PCOS-associated 11 SNP loci 
(LHCGR, THADA, FSHR, KHDRBS3, 
YAP1, RAB5B and TOX3) were found to have 
a significant relationship with PCOS after 
Bonferroni correction. We did not examine 
these gene loci in our study. 
We thought that this difference is caused by the 
ethnic diversity   and use of different 
genotyping techniques among studies. The 
BMI of the women in our study was generally 
below 30. The absence of metabolic diseases 
and of excessive obesity in all women included 
in the study ensured that the comparison 
between PCOS and healthy patients was 
independent of metabolic events and obesity. 
Although the low number of patients in our 
study was seen as a limitation of our study, the 
fact that both groups were composed of 
individuals without insulin resistance and 
without metabolic diseases may have enabled 
us to reveal the relationship with PCOS more 
accurately. 
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In conclusion, no relation was found between 
genotype distribution and allele frequency of 
the FABP1 gene rs2197076 polymorphism in 
patients with PCOS. Further studies are needed 
on this subject. 
 
Acknowledgments 
The authors would like to thank Bolu Abant 
İzzet Baysal University Medical Genetics 
department for its contributions and 
cooperation in this project. 
Conflict of Interest: No conflict of interest was 
declared by the authors. 
Funding sources: None  
Informed Consent: Written informed consent 
was obtained from the patients who 
participated in this study. 
 
References 
[1] Azziz R, Woods KS, Reyna R, Key TJ, 
Knochenhauer ES, Yildiz BO. The 
prevalence and features of the polycystic 
ovary syndrome in an unselected 
population. J Clin Endocrinol Metab. 
2004;89(6): 2745–49. 
[2] The Amsterdam ESHRE/ASRM-
Sponsored 3rd PCOS Consensus 
Workshop Group. Consensus on women’s 
health aspects of polycystic ovary 
syndrome (PCOS) Hum 
Reprod. 2012;27(1):14–24.  
[3] Luque-Ramírez M, Escobar-Morreale HF. 
Polycystic ovary syndrome as a paradigm  
for prehypertension, prediabetes, and 
preobesity. Curr Hypertens Rep. 
2014;16(12):500. 
[4] Franks S, Mc Carthy M, Hardy K. 
Development of polycystic ovary 
syndrome: involvement of genetic and 
environmental factors. Int J 
Androl. 2006;29(1):278–85.  
[5] De Leo V, Musacchio MC, Cappelli 
V, Massaro MG, Morgante G, Petraglia F. 
Genetic, hormonal and metabolic aspects 
of PCOS: an update. Reprod Biol 
Endocrinol. 2016;14(1):38.  
[6] Xita N, Georgiou I, Tsatsoulis A. The 
genetic basis of polycystic ovary 
syndrome. Eur J 
Endocrinol. 2002;147(69:717–25. 
[7] Chen L, Hu LM, Wang YF, Yang 
HY, Huang XY, Zhou W, Sun HX. 
Genome-wide association study for SNPs 
associated with PCOS in human patients. 
Exp Ther Med. 2017;14(5):4896-4900. 
[8] Zimmerman AW, Veerkamp JH. New 
insights into the structure and function of 
fatty acid-binding proteins. Cell Mol Life 
Sci. 2002;59(7):1096–116.  
[9] Binas B, Erol E. FABPs as determinants of 
myocellular and hepatic fuel metabolism. 
Mol Cell Biochem. 2007;299(1-2):75-84.  
[10] Chmurzyńska A. The multigene family of 
fatty acid-binding proteins (FABPs): 
function, structure and polymorphism. J 
Appl Genet. 2006;47(1):39-48.  
[11] Haunerland NH, Spener F. Fatty acid-
binding proteins--insights from genetic 
manipulations. Prog Lipid Res. 2004 
;43(4):328-49.  
[12] Huang H, McIntosh AL, Martin GG, 
Landrock D, Chung S, Landrock KK, et al. 
FABP1: A Novel Hepatic 
Endocannabinoid and Cannabinoid 
Binding Protein. Biochemistry. 
2016;55(37):5243-55. 
[13] Mansego ML, Martínez F, Martínez-Larrad 
MT, Zabena C, Rojo G, Morcillo S, et al. 
Common variants of the liver fatty acid 
binding protein gene influence the risk of 
type 2 diabetes and insulin resistance in 
Spanish population. PLoS One. 2012;7: 
e31853. 
                                                        Karakuz et al.  Exp Biomed Res 2019; 2(1):29-36 
   
 
36 
 
[14] Kosova G, Urbanek M. Genetics of the 
polycystic ovary syndrome. Mol cell 
endocrinol. 2013;373(1-2):29-38. 
[15] Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi 
Y et al. Genome-wide association study 
identifies susceptibility loci for polycystic 
ovary syndrome on chromosome 2p16.3, 
2p21 and 9q33.3. Nat 
Genet. 2011;43(1):55-59.  
[16] Lee H, Oh JY, Sung YA, Chung HW. A 
genetic risk score is associated with 
polycystic ovary syndrome-related traits. 
Hum Reprod. 2016;31(1):209-15. 
[17] Lerchbaum E, Trummer O, Giuliani A, 
Gruber HJ, Pieber TR, Obermayer-Pietsch 
B.   Susceptibility loci for polycystic ovary 
syndrome on chromosome 2p16.3, 2p21, 
and 9q33.3 in a cohort of Caucasian women. 
Horm Metab Res. 2011;43(11):743-47.  
[18] Goodarzi MO, Jones MR, Li X, Chua AK, 
Garcia OA, Chen YD et al.  Replication of 
association of DENND1A and THADA 
variants with polycystic ovary syndrome in 
European cohorts. J Med 
Genet. 2012;49(2):90-95. 
[19] Xue H, Zhao H, Liu X, Zhao YR, Chen ZJ, 
Ma J. Association of single-nucleotide 
polymorphisms rs2197076 and rs2241883 
of FABP1 gene with polycystic ovary 
syndrome. J Assist Reprod Genet. 
2016;33(1):75-83. 
[20] Rashid N1, Nigam A, Saxena P, Jain 
SK, Wajid S.  Association of IL-1β, IL-1Ra 
and FABP1 gene polymorphisms with the 
metabolic features of polycystic ovary 
syndrome.  Inflamm Res. 2017;66(7):621-
36. 
[21] Cui L, Li G, Zhong W, Bian Y, Su S, Sheng 
Y et al.  Polycystic ovary syndrome 
susceptibility single nucleotide 
polymorphisms in women with a 
single PCOS clinical feature. Hum Reprod. 
2015;30(3):732-36. 
 
